Regional reportWhere is it happening?
Japan
An established academic field, now carrying a wireless implant toward a first company-sponsored trial.
AcceleratingConfidence moderate
Research trajectory, from scholarly works by author country: +14% a year over the latest three years, −1% in the three before. Data as of 8 Oct 2026.
Field snapshot
- 82
- scholarly works in 2025
- 2% of the world count; 4% in 2019
- 46
- PubMed papers in 2025
- held as individual records
- 0
- registered studies open now
- 0 with an implanted interface
- 2
- companies profiled
- in 1 country
- $2.2M
- disclosed in recorded rounds
- 1 round; a sample
- 0
- regulatory milestones recorded
- kept apart by type
Profiled companies at their headquarters, from the year each was founded.
2 marks on the companies layer in 2026, Japan. Hover a mark, or use the list.
Marks are records, not decoration. Country marks sit at the centre of the country, not at an institution. Mark area follows the count, so a few large countries dominate; use the region zoom to read the rest. 3 profiled companies have not disclosed a location and are not placed. 36 countries with a small number of works have no position recorded and are not drawn. Clinical counts come from ClinicalTrials.gov and under-count studies outside the United States.
Research momentum
Authors in Japan published 82 scholarly works on brain-computer interfaces in 2025, +1% on the year before. Over the latest three years output grew +14% a year, against −1% in the three years before; the world as a whole grew +23% a year.
| Year | Japan |
|---|---|
| 2010 | 44 |
| 2011 | 46 |
| 2012 | 55 |
| 2013 | 54 |
| 2014 | 56 |
| 2015 | 55 |
| 2016 | 65 |
| 2017 | 66 |
| 2018 | 81 |
| 2019 | 58 |
| 2020 | 77 |
| 2021 | 64 |
| 2022 | 56 |
| 2023 | 63 |
| 2024 | 81 |
| 2025 | 82 |
| 2026 | 76 |
Companies and initiatives
Clinical programmes
ClinicalTrials.gov lists 0 open studies with a site in Japan, 0 of them involving an implanted interface. 0 studies started in 2025.
None of the studies we profile in detail has a site here.
Capital
- 2026$2.2MJiMED Series BReported as JPY 330 million. Converted by the Briefing at about 150 yen to the dollar; the source gives no dollar figure.
Disclosed funding only: the rounds recorded by the Briefing, not a market total.
Regulatory environment
Medical devices are reviewed by the Pharmaceuticals and Medical Devices Agency and approved by the Ministry of Health, Labour and Welfare. Company-sponsored trials are notified to the agency before they start.
Trials are registered in the Japan Registry of Clinical Trials, which we do not read yet.
Institutions in the corpus
Osaka University
Suita, Japan
Institutions appear here because a profiled study or paper names them. It is not a ranking, and many active groups are missing.
Latest developments
- 2026JiMED Series B of ¥330 million reported, led by Keio Innovation Initiative, to fund the start of the ALS trial.
- 10 Jul 2024Araya Preprint: speech decoded from 175 hours of scalp EEG recorded from one healthy participant reading aloud, with 48% top-one and 76% top-ten accuracy in an open vocabulary.
- 2020JiMED Company founded in Osaka.
- Dec 2013Araya Founded in Tokyo, according to the company.
Open questions and outlook
- Implanted BCIs used at homeHow soon is everyday home use the norm for study participants, not the exception?Now · confidence high
- Fully implanted, wireless, high channel countWhen do the systems with the best signals lose the connector through the skin?1–2 years · confidence moderate
Forward-looking judgements by The BCI Briefing, with their reasoning on the Trends page. Uncertain by nature.
What we cannot see here
- We profile two companies and cite no Japanese-language source. Treat this page as a first sketch of the region, not a survey.
- Japan Registry of Clinical Trials (jRCT) is not connected. Not yet connected.
Known to us, not yet verified
- LIFESCAPES (non-invasive BMI for stroke rehabilitation)
- Japanese national programmes (AMED Brain/MINDS, Moonshot)
Leads are pointers for us to check: a study sponsor in a registry, a name in a report. They say nothing yet about what an organisation does, and none is counted anywhere on this site until it has a profile with sources.
Sources cited for this region’s profiles are in English.